Albert Einstein's brain

Longtime Mayo Clinic Neurologist Dr. Richard J. Caselli Joins SPARK Neuro as Medical Director

Retrieved on: 
Tuesday, April 16, 2024
Alzheimer's disease, FDA, Mayo Clinic, Bangladesh Technical Education Board, Research, Albert Einstein's brain, Dementia, Clinical professor, Patient experience, Patient, Neurology, Neuro, EEG, Patient satisfaction, Medical director, Medical device

LOS ANGELES, April 16, 2024 /PRNewswire/ -- SPARK Neuro, a leader in brain health diagnostics, announces the appointment of Dr. Richard J. Caselli as its Medical Director.

Key Points: 
  • LOS ANGELES, April 16, 2024 /PRNewswire/ -- SPARK Neuro, a leader in brain health diagnostics, announces the appointment of Dr. Richard J. Caselli as its Medical Director.
  • With a 35-year career at the Mayo Clinic, Dr. Caselli brings extensive expertise and leadership in neurology and cognitive aging to SPARK Neuro.
  • During his tenure at Mayo Clinic, Dr. Caselli and his team collaborated with SPARK Neuro on several research initiatives funded by the National Institutes of Health.
  • Dr. Caselli's distinguished career includes serving as Chair of the Department of Neurology, Medical Director of Patient Experience, and Director of Research at the Mayo Clinic.

The McKnight Brain Research Foundation Releases Survey Showing Majority of People Feel Uninformed About What's Normal and What to Expect as the Brain Ages

Retrieved on: 
Friday, March 22, 2024
Research, Depression, Friends, Brain, Organization, Mental health, Dementia, Exercise, Learning, Brain Works, Memory, Vegetable, Diabetes, Risk, Heart rate, Conditional sentence, Aging brain, Sleep, Perspiration, Anxiety, Doctor of Philosophy, MD, Thought, Albert Einstein's brain, Body, Amnesia, Diet, Fruit, Language, Family, Ageing, Fear, Mobile phone

ORLANDO, Fla., March 22, 2024 /PRNewswire/ -- The McKnight Brain Research Foundation (MBRF) today released findings from a new survey showing one-third of Americans feel uninformed about normal brain aging. In addition, 87% of Americans are concerned about experiencing age-related memory loss and a decline in brain function as they grow older. To educate the public about normal brain aging, also known as cognitive aging, the MBRF is launching a new campaign, Brain Works – Optimize Your Brain Span. 

Key Points: 
  • Foundation Launching New Campaign – Brain Works: Optimize Your Brain Span –
    ORLANDO, Fla., March 22, 2024 /PRNewswire/ -- The McKnight Brain Research Foundation (MBRF) today released findings from a new survey showing one-third of Americans feel uninformed about normal brain aging.
  • To educate the public about normal brain aging, also known as cognitive aging, the MBRF is launching a new campaign, Brain Works – Optimize Your Brain Span.
  • "For the past 25 years, the McKnight Brain Research Foundation has been a leading supporter of research to better understand and alleviate the effects of age-related cognitive decline and memory loss," said Michael L. Dockery, MD, Chair of the McKnight Brain Research Foundation.
  • The MBRF survey showed that only 32% of respondents believe they can take action to help control their brain health as they age.

OSC announces Seniors Expert Advisory Committee members for 2024

Retrieved on: 
Wednesday, January 10, 2024
Well, Volunteering, PACE, Ethics, Partner, Face, Abuse, University, Medicine, Salmon, Risk, Banking in Canada, National initiative, CIRO, Consent, Law society, Albert Einstein's brain, Decision, Social work, Old age, Dementia, Law enforcement, Policy, Rights, Law, UN, Environment, TMU, OSC, NASAA, Ageism, Education, Communication, Care, Elder abuse, Royal Bank, Person, RBC, Executive, Memory, Senior, EAPO, Ontario Securities Commission, Toronto Metropolitan University, Government, Trust, Blog, CCAA, United Nations, Nursing

TORONTO, Jan. 10, 2024 /CNW/ - The Ontario Securities Commission (OSC) today announced the membership of its Seniors Expert Advisory Committee (SEAC) for the 2024 term.

Key Points: 
  • TORONTO, Jan. 10, 2024 /CNW/ - The Ontario Securities Commission (OSC) today announced the membership of its Seniors Expert Advisory Committee (SEAC) for the 2024 term.
  • First launched in 2016, SEAC has provided valuable insights on and contributions to OSC initiatives supporting seniors, including the development and implementation of the OSC Seniors Strategy.
  • Members provide diverse perspectives on issues and challenges facing older investors, drawing on their expertise in sectors including financial services, law, law enforcement, academia, medicine and seniors' advocacy.
  • The OSC would like to thank former SEAC members Alexis Wenzowski, Harold Geller, James (Jim) Turner, Kavina Nagrani and Keith Sjorgen for their service and contributions.

Terran Biosciences Receives FDA Clearance for NM-101, the industry’s first software for the analysis of neuromelanin-sensitive MRI

Retrieved on: 
Wednesday, December 20, 2023
Software, Research, Radiology, Pharmaceutical, Mental Health, Technology, Hospitals, Health Technology, Science, Neurology, Biotechnology, FDA, Health, Psychiatry, Associate, MRI, Locus coeruleus, DSM-IV codes, Physician, Albert Einstein's brain, Hospital, Brain, Doctor of Philosophy, News, PACS, Substantia nigra, Columbia University, Mental Hygiene, University, Biomedicine, CNS, Molecular medicine, Schizophrenia, Assistant, Patient, Diagnosis, Meta-analysis, Neuroscience, Therapy, Algorithm, Automation, Medical imaging

Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.

Key Points: 
  • Terran Biosciences, Inc. ("Terran"), a biotech platform company developing therapeutics and technologies for patients with neuropsychiatric illnesses, has received FDA clearance to market NM-101, a cloud-based software platform to analyze neuromelanin-sensitive MRI scans.
  • Currently, there is no other FDA-cleared software indicated for the analysis of neuromelanin MRI on the market, making Terran’s technology the world’s first.
  • NM-101 is a cloud-based analysis platform that is able to seamlessly integrate into existing workflows at hospitals and imaging centers.
  • NM-101 contains algorithms that enabled for the first time the fully automated analysis and the cross-scanner harmonization of neuromelanin MRI scans [8-10,12,13].

Innovative Researcher Ben Zimmerman Awarded Grant to Propel Aging-Related Research

Retrieved on: 
Thursday, November 16, 2023
MRF, Research, Oklahoma Medical Research Foundation, Multimedia, Naturopathy, RHI, Science, Albert Einstein's brain, Dementia, Ageing, Quality of life, NUNM, National university, Pharmaceutical industry, Centella

PORTLAND, Ore., Nov. 16, 2023 /PRNewswire/ -- Ben Zimmerman, Ph.D., a postdoctoral researcher investigator at the Helfgott Research Institute at the National University of Natural Medicine, has received a grant from the Medical Research Foundation (MRF) to advance the understanding of aging-related health.

Key Points: 
  • PORTLAND, Ore., Nov. 16, 2023 /PRNewswire/ -- Ben Zimmerman, Ph.D., a postdoctoral researcher investigator at the Helfgott Research Institute at the National University of Natural Medicine, has received a grant from the Medical Research Foundation (MRF) to advance the understanding of aging-related health.
  • The research will investigate whether a four-week treatment with Centella asiatica can enhance peripheral arterial endothelial function, an indicator of vascular health.
  • Dr. Zimmerman's approach, centered on vascular health and a traditional herbal remedy, is a refreshing departure from conventional avenues of research.
  • Founded in 2003, NUNM's Helfgott Research Institute is a professionally independent, non-profit research institute conducting rigorous, high quality research on the art and science of healing.

SYNAPS Dx Observes September as World Alzheimer’s Month and Healthy Aging Month: Celebrates Researchers, Providers and Patients

Retrieved on: 
Tuesday, September 26, 2023
Research, Mental Health, Nursing, Seniors, Neurology, Biotechnology, Managed Care, Consumer, Health, Science, DISCERN, Synaptic, Obesity, Depression, Software-defined, Diabetes, Hearing loss, Clinical Laboratory, Albert Einstein's brain, Risk, Brain, Dementia, Medicare, Gold standard, CLIA, HIV disease progression rates, Patient, Kool-Aid, Diagnosis, AD, Smoking, Autopsy, Amato, Pharmaceutical industry, Medical device, Medical imaging

The 2023 theme ‘Never too early, never too late’ highlights the need for an early and accurate diagnosis of AD and the importance of recognizing AD risk factors.

Key Points: 
  • The 2023 theme ‘Never too early, never too late’ highlights the need for an early and accurate diagnosis of AD and the importance of recognizing AD risk factors.
  • Awareness of risk reduction strategies is crucial, especially for those who are not yet showing symptoms.
  • A minimally invasive, 3mm skin punch biopsy , DISCERN can be administered in a primary care setting.
  • DISCERN assesses factors closely related to the formation of synaptic connections in the brain as well as the formation of amyloid plaque and abnormal tau.

Relativity Space Signs Lease on Historic NASA Test Stand

Retrieved on: 
Thursday, September 7, 2023
Engineering, Technology, Satellite, Aerospace, Manufacturing, Hardware, Constellation, Saturn V, Partnership, Rejuvenation, Space Shuttle program, Apollo program, E-4, Albert Einstein's brain, Space Shuttle, 3D, E-2, Multimedia, Research, Tenant, EULA, Saturn, NASA, Entrepreneurship, Constellation program, Relativity Space, E-1, Terran, John C. Stennis, Stennis Space Center, Communications satellite, Gulf Coast of the United States, Relativity

Relativity Space , the preeminent 3D printed rocket company, has signed an enhanced use lease agreement (EULA) on the vertical test stand at the A-2 complex within NASA’s historic Stennis Space Center in Hancock County, Mississippi.

Key Points: 
  • Relativity Space , the preeminent 3D printed rocket company, has signed an enhanced use lease agreement (EULA) on the vertical test stand at the A-2 complex within NASA’s historic Stennis Space Center in Hancock County, Mississippi.
  • View the full release here: https://www.businesswire.com/news/home/20230907155639/en/
    A rendering of Terran R's first stage on the A-2 Test Stand at NASA's Stennis Space Center (Graphic: Business Wire)
    Established in the 1960s, NASA Stennis is the nation’s largest and most prestigious propulsion test center.
  • “New history is being written at Stennis Space Center as we breathe life into the historic A-2 Test Stand with our Terran R program,” said Tim Ellis, Co-Founder and CEO of Relativity Space.
  • I appreciate the partnership of companies like Relativity Space who are helping Mississippi stay at the leading edge.”
    “The A-2 test stand at Stennis Space Center has a long and storied history as part of the U.S. space program, and the agreement with Relativity Space will extend that record,” said Senator Cindy Hyde-Smith.

Doctors Share Top Five Foods to Prevent Constipation in Light of New Research Linking Alzheimer’s Risk to Gut Microbiome

Retrieved on: 
Thursday, July 20, 2023
Retail, Other Health, Managed Care, General Health, Mental Health, Women, Seniors, Men, Fitness & Nutrition, Science, Other Science, Lifestyle, Food, Beverage, Consumer, Research, Health, Cognition, University, Education, Seed, Public, George Washington University School of Medicine & Health Sciences, Physicians Committee for Responsible Medicine, Albert Einstein's brain, Molina Healthcare, Constipation, Grain boundary strengthening, Vegetable, Doctor of Philosophy, Defecation, AAIC, University of Massachusetts Amherst Department of Food Science, Risk, Ethics, News, Conference, Pharmaceutical industry, MD, Medicine

At the Alzheimer’s Association International Conference (AAIC) in Amsterdam yesterday, new research was presented highlighting the growing body of evidence linking constipation and people’s gut microbiomes to Alzheimer’s disease and brain health.

Key Points: 
  • At the Alzheimer’s Association International Conference (AAIC) in Amsterdam yesterday, new research was presented highlighting the growing body of evidence linking constipation and people’s gut microbiomes to Alzheimer’s disease and brain health.
  • In light of this new evidence, the Physicians Committee for Responsible Medicine, a public health advocacy nonprofit of more than 17,000 doctor members, shares the top five foods for improving gut health and preventing constipation.
  • “We now better understand the problem, that constipation leads to significantly worse cognition,” says Adjunct Professor of Medicine at George Washington University School of Medicine Dr. Neal Barnard , president of the Physicians Committee.
  • Compared to those with bowel movements once daily, constipated participants (bowel movements every three days or more) had significantly worse cognition, equivalent to 3.0 years more of chronological cognitive aging.

ADVANCEMENTS IN TREATMENT, DIAGNOSIS AND RISK REDUCTION STRATEGIES HIGHLIGHTED AT ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

Retrieved on: 
Thursday, July 20, 2023
Cognition, Lund University, CRISPR, University, Observational study, Prevalence, Hearing loss, University of Massachusetts, Trial of the century, Senior counsel, Albert Einstein's brain, Dementia, Research, Brain, Risk, Temperature, Biomarker, Pharmacy, Constipation, Eli Lilly, University of California, Davis, Thought, Amel Association International, Ageing, University of Gothenburg, Alzheimer's Association, AAIC, Defecation, HIV disease progression rates, Physician, Donanemab, Hearing, Kool-Aid, Diagnosis, Mortality, Familial Danish dementia, Rush University Medical Center, Health, Death, Family, Memory, University of Texas at San Antonio, Caregiver, Disease, Residential care, Medical imaging, Pharmaceutical industry, Antibiotics, Alzheimer's disease

AAIC is the premier annual forum for presentation and discussion of the latest Alzheimer's and dementia research.

Key Points: 
  • AAIC is the premier annual forum for presentation and discussion of the latest Alzheimer's and dementia research.
  • This year's conference took place both virtually and in-person in Amsterdam, Netherlands, and attracted over 10,000 attendees and more than 3,000 scientific presentations.
  • The Alzheimer's Association highlighted results from trials of drug and non-drug interventions for Alzheimer's disease at AAIC 2023.
  • Blood tests for Alzheimer's have great potential for improving early diagnosis, diagnostic accuracy and proper treatment of people with Alzheimer's.

ADVANCEMENTS IN TREATMENT, DIAGNOSIS AND RISK REDUCTION STRATEGIES HIGHLIGHTED AT ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

Retrieved on: 
Thursday, July 20, 2023
Cognition, Lund University, CRISPR, University, Observational study, Prevalence, Hearing loss, University of Massachusetts, Trial of the century, Senior counsel, Albert Einstein's brain, Dementia, Research, Brain, Risk, Temperature, Biomarker, Pharmacy, Constipation, Eli Lilly, University of California, Davis, Thought, Amel Association International, Ageing, University of Gothenburg, Alzheimer's Association, AAIC, Defecation, HIV disease progression rates, Physician, Donanemab, Hearing, Kool-Aid, Diagnosis, Mortality, Familial Danish dementia, Rush University Medical Center, Health, Death, Family, Memory, University of Texas at San Antonio, Caregiver, Disease, Residential care, Medical imaging, Pharmaceutical industry, Antibiotics, Alzheimer's disease

AAIC is the premier annual forum for presentation and discussion of the latest Alzheimer's and dementia research.

Key Points: 
  • AAIC is the premier annual forum for presentation and discussion of the latest Alzheimer's and dementia research.
  • This year's conference took place both virtually and in-person in Amsterdam, Netherlands, and attracted over 10,000 attendees and more than 3,000 scientific presentations.
  • The Alzheimer's Association highlighted results from trials of drug and non-drug interventions for Alzheimer's disease at AAIC 2023.
  • Blood tests for Alzheimer's have great potential for improving early diagnosis, diagnostic accuracy and proper treatment of people with Alzheimer's.